205 related articles for article (PubMed ID: 27467954)
1. Syngeneic syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting.
Siurala M; Vähä-Koskela M; Havunen R; Tähtinen S; Bramante S; Parviainen S; Mathis JM; Kanerva A; Hemminki A
Oncoimmunology; 2016 May; 5(5):e1136046. PubMed ID: 27467954
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.
Santos JM; Heiniö C; Cervera-Carrascon V; Quixabeira DCA; Siurala M; Havunen R; Butzow R; Zafar S; de Gruijl T; Lassus H; Kanerva A; Hemminki A
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940588
[TBL] [Abstract][Full Text] [Related]
3. Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.
Clubb JHA; Kudling TV; Girych M; Haybout L; Pakola S; Hamdan F; Cervera-Carrascon V; Hemmes A; Grönberg-Vähä-Koskela S; Santos JM; Quixabeira DCA; Basnet S; Heiniö C; Arias V; Jirovec E; Kaptan S; Havunen R; Sorsa S; Erikat A; Schwartz J; Anttila M; Aro K; Viitala T; Vattulainen I; Cerullo V; Kanerva A; Hemminki A
Front Immunol; 2023; 14():1060540. PubMed ID: 36817448
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.
Santos JM; Cervera-Carrascon V; Havunen R; Zafar S; Siurala M; Sorsa S; Anttila M; Kanerva A; Hemminki A
Mol Ther; 2018 Sep; 26(9):2243-2254. PubMed ID: 30017877
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy.
Havunen R; Siurala M; Sorsa S; Grönberg-Vähä-Koskela S; Behr M; Tähtinen S; Santos JM; Karell P; Rusanen J; Nettelbeck DM; Ehrhardt A; Kanerva A; Hemminki A
Mol Ther Oncolytics; 2017 Mar; 4():77-86. PubMed ID: 28345026
[TBL] [Abstract][Full Text] [Related]
6. Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers.
Santos J; Heiniö C; Quixabeira D; Zafar S; Clubb J; Pakola S; Cervera-Carrascon V; Havunen R; Kanerva A; Hemminki A
Cells; 2021 Apr; 10(5):. PubMed ID: 33922052
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control.
Quixabeira DCA; Zafar S; Santos JM; Cervera-Carrascon V; Havunen R; Kudling TV; Basnet S; Anttila M; Kanerva A; Hemminki A
Front Immunol; 2021; 12():674400. PubMed ID: 34084172
[TBL] [Abstract][Full Text] [Related]
8. Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy.
Santos JM; Havunen R; Siurala M; Cervera-Carrascon V; Tähtinen S; Sorsa S; Anttila M; Karell P; Kanerva A; Hemminki A
Int J Cancer; 2017 Oct; 141(7):1458-1468. PubMed ID: 28614908
[TBL] [Abstract][Full Text] [Related]
9. Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine.
Quixabeira DCA; Jirovec E; Pakola S; Havunen R; Basnet S; Santos JM; Kudling TV; Clubb JHA; Haybout L; Arias V; Grönberg-Vähä-Koskela S; Cervera-Carrascon V; Pasanen A; Anttila M; Tapper J; Kanerva A; Hemminki A
Cancer Gene Ther; 2023 Nov; 30(11):1543-1553. PubMed ID: 37666898
[TBL] [Abstract][Full Text] [Related]
10. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
11. Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors.
Thomas MA; Spencer JF; Wold WS
Methods Mol Med; 2007; 130():169-83. PubMed ID: 17401172
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors.
Cervera-Carrascon V; Quixabeira DCA; Havunen R; Santos JM; Kutvonen E; Clubb JHA; Siurala M; Heiniö C; Zafar S; Koivula T; Lumen D; Vaha M; Garcia-Horsman A; Airaksinen AJ; Sorsa S; Anttila M; Hukkanen V; Kanerva A; Hemminki A
Mol Ther Oncolytics; 2020 Jun; 17():47-60. PubMed ID: 32322662
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.
Clubb JHA; Kudling TV; Heiniö C; Basnet S; Pakola S; Cervera Carrascón V; Santos JM; Quixabeira DCA; Havunen R; Sorsa S; Zheng V; Salo T; Bäck L; Aro K; Tulokas S; Loimu V; Hemminki A
Front Immunol; 2022; 13():794251. PubMed ID: 35355980
[TBL] [Abstract][Full Text] [Related]
14. [Clinical application of adoptive immunotherapy by cytotoxic T lymphocytes induced from tumor-infiltrating lymphocytes].
Yamaue H; Tanimura H; Tsunoda T; Iwahashi M; Tani M; Inoue M; Tamai M
Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):978-89. PubMed ID: 2391445
[TBL] [Abstract][Full Text] [Related]
15. Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.
Steger GG; Pierce WC; Figlin R; Czernin J; Kaboo R; DeKernion JB; Okarma T; Belldegrun A
Clin Immunol Immunopathol; 1994 Aug; 72(2):237-47. PubMed ID: 8050198
[TBL] [Abstract][Full Text] [Related]
16. New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster.
Spencer JF; Sagartz JE; Wold WS; Toth K
Cancer Gene Ther; 2009 Dec; 16(12):912-22. PubMed ID: 19478829
[TBL] [Abstract][Full Text] [Related]
17. An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage.
Pakola S; Quixabeira DCA; Kudling TV; Clubb JHA; Grönberg-Vähä-Koskela S; Basnet S; Jirovec E; Arias V; Haybout L; Heiniö C; Santos JM; Cervera-Carrascon V; Havunen R; Anttila M; Hemminki A
Front Immunol; 2023; 14():1171083. PubMed ID: 37475863
[TBL] [Abstract][Full Text] [Related]
18. Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer.
Santin AD; Bellone S; Palmieri M; Bossini B; Cane' S; Bignotti E; Roman JJ; Cannon MJ; Pecorelli S
Int J Gynecol Cancer; 2004; 14(1):64-75. PubMed ID: 14764031
[TBL] [Abstract][Full Text] [Related]
19. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.
Bramante S; Kaufmann JK; Veckman V; Liikanen I; Nettelbeck DM; Hemminki O; Vassilev L; Cerullo V; Oksanen M; Heiskanen R; Joensuu T; Kanerva A; Pesonen S; Matikainen S; Vähä-Koskela M; Koski A; Hemminki A
Int J Cancer; 2015 Oct; 137(7):1775-83. PubMed ID: 25821063
[TBL] [Abstract][Full Text] [Related]
20. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
Hayakawa K; Salmeron MA; Parkinson DR; Markowitz AB; von Eschenbach AC; Legha SS; Balch CM; Ross MI; Augustus LB; Itoh K
J Immunother (1991); 1991 Oct; 10(5):313-25. PubMed ID: 1790139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
